StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.11−0.07 (-5.93%)

Close on Nov 18, 2026Market cap $48.44MP/E –Yield –

Gain Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Gain Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $55.18K, down 60.6% year over year. For fiscal 2023 it was $55.18K, down 60.6% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$55.18K-60.6%
FY2022Dec 31, 2022$140.11K-15.1%
FY2021Dec 31, 2021$164.99K+471.3%
FY2020Dec 31, 2020$28.88K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$55.18K+22.6%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$95.10K+6.6%
Q1 FY2022Mar 31, 2022$45.01K+754.2%
Q4 FY2021Dec 31, 2021$43.21K+372.8%
Q3 FY2021Sep 30, 2021$27.35K+308.4%
Q2 FY2021Jun 30, 2021$89.17K+1299.2%
Q1 FY2021Mar 31, 2021$5.27K-21.0%
Q4 FY2020Dec 31, 2020$9.14K–
Q3 FY2020Sep 30, 2020$6.70K–
Q2 FY2020Jun 30, 2020$6.37K–
Q1 FY2020Mar 31, 2020$6.67K–

More Gain Therapeutics figures

See a number that looks wrong?